Immune-related gene signature improves prognosis prediction in patients with breast cancer and associates it with tumor immunity and inflammatory response.

IF 2.4 3区医学 Q2 OBSTETRICS & GYNECOLOGY

BMC Women's Health Pub Date : 2024-08-07 DOI:10.1186/s12905-024-03289-4

Haiping Zhang, Lu Sun, Jingjing Liu, Jing Wang, Lingchao Meng, Yuan Gao, Jingwu Li, Qi Zhou

{"title":"Immune-related gene signature improves prognosis prediction in patients with breast cancer and associates it with tumor immunity and inflammatory response.","authors":"Haiping Zhang, Lu Sun, Jingjing Liu, Jing Wang, Lingchao Meng, Yuan Gao, Jingwu Li, Qi Zhou","doi":"10.1186/s12905-024-03289-4","DOIUrl":null,"url":null,"abstract":"Background: The prognostic potential of immune-related genes, particularly immune checkpoint inhibitors (ICIs) and long non-coding RNAs (lncRNAs), is gaining attention for evaluating the prognosis of breast cancer patients.Methods: We analyzed 23 datasets to identify 15 ICI-related mRNAs and 5 immune-related lncRNAs, creating a robust immune score (IS). This score was used to classify patients into high and low IS groups and assess their survival outcomes.Results: Patients with high IS showed significantly poorer overall survival (OS) and progression-free survival (PFS) compared to those with low IS. Multivariate Cox regression analysis confirmed IS as an independent prognostic factor. Additionally, high IS was associated with higher mutation loads and neoantigen profiles, while low IS correlated with enhanced immune cell infiltration.Conclusions: The immune score developed from ICI-related mRNAs and lncRNAs effectively predicts the prognosis of breast cancer patients and highlights the differential immune and inflammatory responses between patients with varying levels of immune score. This underscores the relevance of IS in guiding therapeutic decisions and tailoring patient management strategies in clinical settings.","PeriodicalId":9204,"journal":{"name":"BMC Women's Health","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304607/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Women's Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12905-024-03289-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The prognostic potential of immune-related genes, particularly immune checkpoint inhibitors (ICIs) and long non-coding RNAs (lncRNAs), is gaining attention for evaluating the prognosis of breast cancer patients.

Methods: We analyzed 23 datasets to identify 15 ICI-related mRNAs and 5 immune-related lncRNAs, creating a robust immune score (IS). This score was used to classify patients into high and low IS groups and assess their survival outcomes.

Results: Patients with high IS showed significantly poorer overall survival (OS) and progression-free survival (PFS) compared to those with low IS. Multivariate Cox regression analysis confirmed IS as an independent prognostic factor. Additionally, high IS was associated with higher mutation loads and neoantigen profiles, while low IS correlated with enhanced immune cell infiltration.

Conclusions: The immune score developed from ICI-related mRNAs and lncRNAs effectively predicts the prognosis of breast cancer patients and highlights the differential immune and inflammatory responses between patients with varying levels of immune score. This underscores the relevance of IS in guiding therapeutic decisions and tailoring patient management strategies in clinical settings.

查看原文本刊更多论文

免疫相关基因特征可改善乳腺癌患者的预后预测，并与肿瘤免疫和炎症反应相关。

背景：免疫相关基因，尤其是免疫检查点抑制剂（ICIs）和长非编码RNAs（lncRNAs）的预后潜力在评估乳腺癌患者预后方面越来越受到关注：我们分析了23个数据集，确定了15个与ICI相关的mRNA和5个与免疫相关的lncRNA，创建了一个稳健的免疫评分（IS）。该评分用于将患者分为高ISI组和低ISI组，并评估他们的生存结果：结果：与低IS患者相比，高IS患者的总生存期（OS）和无进展生存期（PFS）明显较差。多变量考克斯回归分析证实，IS是一个独立的预后因素。此外，高IS与较高的突变负荷和新抗原谱相关，而低IS与免疫细胞浸润增强相关：结论：根据 ICI 相关 mRNAs 和 lncRNAs 得出的免疫评分能有效预测乳腺癌患者的预后，并强调了不同免疫评分水平的患者之间存在不同的免疫和炎症反应。这凸显了IS在指导临床治疗决策和定制患者管理策略方面的相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Women's Health OBSTETRICS & GYNECOLOGY-

CiteScore

3.40

自引率

4.00%

发文量

444

审稿时长

>12 weeks

期刊介绍： BMC Women''s Health is an open access, peer-reviewed journal that considers articles on all aspects of the health and wellbeing of adolescent girls and women, with a particular focus on the physical, mental, and emotional health of women in developed and developing nations. The journal welcomes submissions on women''s public health issues, health behaviours, breast cancer, gynecological diseases, mental health and health promotion.